Department Of Medicine
Dr. Parag Khatavkar
Pulmonary rehabilitation delivered in low resource settings for people with chronic respiratory disease: a 3-arm assessor-blind randomised implementation trial
Dr. Pradeep D’Costa
A prospective, multicentre, randomised, active-controlled, observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate the safety, tolerability and immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy subjects
Cardiovascular Department
Dr. Milind Gadkar
A Phase 3, randomised, double-blind, placebo-controlled, event-driven study to demonstrate the efficacy and safety of Milvexian, an Oral Factor XIa Inhibitor, after a recent acute coronary syndrome. (LIBREXIA-ACS).
“A Phase 3, randomised, double-blind, double-dummy, parallel group, active controlled study to evaluate the efficacy and safety of Milvexian, an Oral Factor Xla Inhibitor, versus Apixaban in participants with Atrial Fibrillation (LIBREXIA-AF)”
“HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation (EX6018-4915)”
A multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%)
International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA)